Analysis of vanishing endometrial cancer by pathological types.
endometrial cancer
endometrioid
grade
vanishing
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
25
04
2022
received:
26
11
2021
accepted:
07
05
2022
pubmed:
11
6
2022
medline:
11
8
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
We asked why endometrial cancer sometimes vanishes. A total of 454 patients diagnosed with endometrioid-type endometrial cancer (EC) (via endometrial sampling) and treated in our clinic over the past 5 years were enrolled. The patients were divided into two groups: vanishing and residual, depending on whether a tumor was detected in the postoperative hysterectomy specimen. Patient age, numbers of pregnancies and deliveries, menopausal status, systemic disease status, hemogram parameters, International Federation of Gynecology and Obstetrics (FIGO) grade, and invasion status (evident on magnetic resonance imaging [MRI]) were compared between the groups. ECs vanished in 42 (9.25%) patients. The vanishing rates were 19.7% (37/187) in FIGO grade 1 patients, 2.1% (5/238) in grade 2 patients, and 0% (0/29) in grade 3 patients. The average age was lower in the vanishing than the residual group, but the premenopausal status and grade 1 tumor rates were higher (both p < 0.001). An absence of invasion (as revealed by MRI) was more common in the vanishing group (p < 0.001). No recurrence developed in the vanishing group, but recurrences were noted in 3.3% (14/412) of the residual group. There were no significant between-group differences in any of the numbers of pregnancies or births, systemic disease status, or hemogram parameters (all p > 0.05). Vanishing EC is more likely in premenopausal women with endometrioid grade 1 EC (as revealed by endometrial biopsy) who lack myometrial invasion on MRI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2175-2179Informations de copyright
© 2022 Japan Society of Obstetrics and Gynecology.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
Chambers JT, Chambers SK. Endometrial sampling: when? Where? Why? With what? Clin Obstet Gynecol. 1992;35(1):28-39.
Ferry J, Farnsworth A, Webster M, Wren B. The efficacy of the pipelle endometrial biopsy in detecting endometrial carcinoma. Aust N Z J Obstet Gynaecol. 1993;33(1):76-8.
Sanam M, Majid MM. Comparison the diagnostic value of dilatation and curettage versus endometrial biopsy by Pipelle-a clinical trial. Asian Pac J Cancer Prev. 2015;16(12):4971-5.
Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol. 1991;77(6):954-6.
Stovall TG, Solomon SK, Ling FW. Endometrial sampling prior to hysterectomy. Obstet Gynecol. 1989;73(3 pt 1):405-9. Erratum in: Obstet Gynecol 1989;74(1):105.
Goldstein NS, Bégin LR, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon". Am J Surg Pathol. 1995;19(9):1002-9.
DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol. 1997;21(2):174-8.
Bostwick DG, Bostwick KC. 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004;94(1):57-8.
Peddu P, Huang D, Kane PA, Karani JB, Knisely AS. Vanishing liver tumours. Clin Radiol. 2008;63(3):329-39.
Bhatia P, Deniwar A, Mohamed HE, et al. Vanishing tumors of thyroid: histological variations after fine needle aspiration. Gland Surg. 2016;5(3):270-7.
Dubé V, Macdonald D, Allingham-Hawkins DJ, Kamel-Reid S, Colgan TJ. Vanishing endometrial carcinoma. Int J Gynecol Pathol. 2007;26(3):271-7.
Kumtepe Y, Ulug P, Delibas I, Demirci E. Two cases of vanishing endometrial carcinoma. Res J Med Sci. 2011;5:276-9.
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019;38 Suppl 1(Iss 1 Suppl 1):64-74.
Bharani V, Rai B, Rajwanshi A, et al. Evanescence of endometrial carcinomas in hysterectomy specimens: observations on the "vanishing cancer" phenomenon. Int J Surg Pathol. 2019;27(1):43-7.
Öz M, Karalök A, Şirvan L, et al. Vanishing endometrial carcinoma in hysterectomy specimens: probable implications for fertility sparing management. Turk J Med Sci. 2017;47(6):1744-50.
Ahmed QF, Gattoc L, Al-Wahab Z, et al. Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact. Am J Surg Pathol. 2015;39(2):221-6.
Iitsuka C, Asami Y, Hirose Y, et al. Preoperative magnetic resonance imaging versus intraoperative frozen section diagnosis for predicting the deep myometrial invasion in endometrial cancer: our experience and literature review. J Obstet Gynaecol Res. 2021;47(9):3331-8.
Frei KA, Kinkel K, Bonél HM, Lu Y, Zaloudek C, Hricak H. Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis. Radiology. 2000;216(2):444-9.
Kandoth C, Schultz N, et al. Cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017;145:200-7.
Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113:299-310.
Li Y, Bian Y, Wang K, Wan XP. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. BMC Med Genet. 2019;20(1):202.